Review article · 2026 · Open access

B-cell centrality dictates therapeutic efficacy across autoimmune diseases: a systematic review

Vishakha Hooda, Harsh Goel, Taruna Madan, Alpana Sharma

Frontiers in Immunology, 17, 1906254 · Published 10 September 2026 · DOI 10.3389/fimmu.2026.1906254

Open PDFView at the publisherCite this paper

In brief

“B-cell centrality dictates therapeutic efficacy across autoimmune diseases: a systematic review” is a 2026 review article by Vishakha Hooda and 3 co-authors, published in Frontiers in Immunology. OpenAlex counts 0 citations as of 20 November 2026. It is open access under a CC BY licence: the full text is free to read at Frontiers in Immunology.

Citations
0
References
93
Authors
4

Abstract

Background: B cells play a critical role in autoimmunity through autoantibody production, plasma cell differentiation, antigen presentation, cytokine secretion, and germinal center responses. The clinical efficacy, durability, and safety profiles vary across autoimmune diseases. Therefore, the objective is to assess B-cell therapeutic responses and their correlation with disease pathology in autoimmunity. Methods: Embase, Web of Science, and PubMed were systematically screened for clinical trials published between 2020 and July 2025. A total of 24 clinical trials across five autoimmune conditions-pemphigus vulgaris, myasthenia gravis, rheumatoid arthritis, systemic sclerosis, and Sjögren's syndrome-were evaluated for B-cell-targeted therapy. Interventions included B-cell depletion therapy, CAR-T cell therapy, BTK inhibition, rituximab and its biosimilars, and combination strategies. Results: Across 24 clinical trials, more than 3,500 participants were included. We observed that autoantibody-mediated diseases pemphigus vulgaris and myasthenia gravis had the most superior and durable immune response to B-cell depletion by rituximab and inebilizumab, respectively. BTK inhibition showed rapid but non-durable responses. Immune complex diseases like rheumatoid arthritis and systemic sclerosis showed improvement in activity scores and partial response, and no clinical remission after treatment with rituximab and its biosimilars. The next-generation approach BCMA-directed CAR T-cell therapy showed promising results with potential durability in myasthenia gravis. Combination therapy using belimumab and rituximab resulted in a significantly better clinical outcome than monotherapy in Sjögren's syndrome. Overall, B-cell therapy safety profiles showed no severe adversity and were well tolerated. Conclusions: The success of B-cell therapeutics appears to align with B-cell contribution, disease biology, and the depth of B-cell targeting in autoimmune conditions. Precision targeting is needed to effectively combat autoimmune diseases.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Hooda, V., Goel, H., Madan, T., & Sharma, A. (2026). B-cell centrality dictates therapeutic efficacy across autoimmune diseases: a systematic review. Frontiers in Immunology, 17, 1906254. https://doi.org/10.3389/fimmu.2026.1906254

MLA 9

Hooda, Vishakha, et al. “B-cell centrality dictates therapeutic efficacy across autoimmune diseases: a systematic review.” Frontiers in Immunology, vol. 17, 2026, p. 1906254. https://doi.org/10.3389/fimmu.2026.1906254.

Chicago

Hooda, Vishakha, Harsh Goel, Taruna Madan, and Alpana Sharma. 2026. “B-cell centrality dictates therapeutic efficacy across autoimmune diseases: a systematic review.” Frontiers in Immunology 17: 1906254. https://doi.org/10.3389/fimmu.2026.1906254.

Harvard

Hooda, V. et al. (2026) ‘B-cell centrality dictates therapeutic efficacy across autoimmune diseases: a systematic review’, Frontiers in Immunology, 17, p. 1906254. doi:10.3389/fimmu.2026.1906254.

IEEE

V. Hooda, H. Goel, T. Madan, and A. Sharma, “B-cell centrality dictates therapeutic efficacy across autoimmune diseases: a systematic review,” Frontiers in Immunology, vol. 17, p. 1906254, 2026, doi: 10.3389/fimmu.2026.1906254.

BibTeX

@article{hooda2026cell,
  title     = {{B-cell centrality dictates therapeutic efficacy across autoimmune diseases: a systematic review}},
  author    = {Hooda, Vishakha and Goel, Harsh and Madan, Taruna and Sharma, Alpana},
  journal   = {Frontiers in Immunology},
  year      = {2026},
  volume    = {17},
  pages     = {1906254},
  doi       = {10.3389/fimmu.2026.1906254},
  url       = {https://doi.org/10.3389/fimmu.2026.1906254}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology

  • B-cell depletion therapy
  • B cell-targeted therapy
  • autoimmune disease
  • rituximab
  • inebilizumab
  • BTK inhibition
  • BCMA CAR T-cell therapy
  • belimumab

Work with this paper

Most-cited papers in Immunology and Microbiology

All highly cited Immunology and Microbiology papers

Questions about this paper

How do I cite this paper in APA style?

Hooda, V., Goel, H., Madan, T., & Sharma, A. (2026). B-cell centrality dictates therapeutic efficacy across autoimmune diseases: a systematic review. Frontiers in Immunology, 17, 1906254. https://doi.org/10.3389/fimmu.2026.1906254

How many times has this paper been cited?

0 times, according to OpenAlex on 20 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Frontiers in Immunology: sign in and open the PDF from this page.

Who wrote this paper?

Vishakha Hooda, Harsh Goel, Taruna Madan, Alpana Sharma.

What is the DOI of this paper?

10.3389/fimmu.2026.1906254, permanently at https://doi.org/10.3389/fimmu.2026.1906254. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 20 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.